Nicholas P. Mcandrew

Hematology | Oncology
120 S Spalding Dr Ste 401
Beverly Hills, CA 90212

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications

Medical Therapy for Hormone Receptor-Positive, HER2-Negative Stage I-III Breast Cancer: ASCO Living Guideline, Version 2026.1.0.

Medical Therapy for Hormone Receptor-Positive, HER2-Negative Stage I-III Breast Cancer: ASCO Living Guideline, Version 2026.1.0.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 26, 2026

Tucatinib in Combination With Trastuzumab Deruxtecan in Patients With Previously Treated HER2+ Unresectable Locally Advanced or Metastatic Breast Cancer: An Open-Label Phase 2 Study.

Tucatinib in Combination With Trastuzumab Deruxtecan in Patients With Previously Treated HER2+ Unresectable Locally Advanced or Metastatic Breast Cancer: An Open-Label Phase 2 Study.

Journal: Clinical breast cancer
Published: February 19, 2026

Role of immunotherapy in early breast cancer: past, present, and future.

Role of immunotherapy in early breast cancer: past, present, and future.

Journal: Targeted oncology
Published: May 16, 2025

Socioeconomic disparities in long-term heart failure risk of trastuzumab with or without anthracyclines in early-stage breast cancer: a SEER-Medicare database analysis.

Socioeconomic disparities in long-term heart failure risk of trastuzumab with or without anthracyclines in early-stage breast cancer: a SEER-Medicare database analysis.

Journal: NPJ breast cancer
Published: April 21, 2025

Surgical outcomes following neoadjuvant chemotherapy with and without immunotherapy in patients with triple-negative breast cancer.

Surgical outcomes following neoadjuvant chemotherapy with and without immunotherapy in patients with triple-negative breast cancer.

Journal: Discover oncology
Published: June 26, 2024

Ribociclib plus Endocrine Therapy in Early Breast Cancer.

Ribociclib plus Endocrine Therapy in Early Breast Cancer.

Journal: The New England journal of medicine
Published: March 20, 2024

Rectal Cancer Survival for Residual Carcinoma In Situ Versus Pathologic Complete Response After Neoadjuvant Therapy.

Rectal Cancer Survival for Residual Carcinoma In Situ Versus Pathologic Complete Response After Neoadjuvant Therapy.

Journal: Diseases of the colon and rectum
Published: March 18, 2024

New approaches for human epidermal growth factor receptor 2-low and human epidermal growth factor receptor 2-overexpressing metastatic breast cancer.

New approaches for human epidermal growth factor receptor 2-low and human epidermal growth factor receptor 2-overexpressing metastatic breast cancer.

Journal: Current opinion in obstetrics & gynecology
Published: January 03, 2024

Preclinical and clinical activity of DZD1516, a full blood-brain barrier-penetrant, highly selective HER2 inhibitor.

Preclinical and clinical activity of DZD1516, a full blood-brain barrier-penetrant, highly selective HER2 inhibitor.

Journal: Breast cancer research : BCR
Published: January 05, 2023

Systemic Therapy for Early- and Late-Stage, Human Epidermal Growth Factor Receptor-2-Positive Breast Cancer.

Systemic Therapy for Early- and Late-Stage, Human Epidermal Growth Factor Receptor-2-Positive Breast Cancer.

Journal: Hematology/oncology clinics of North America
Published: November 26, 2022

Ruxolitinib and exemestane for estrogen receptor positive, aromatase inhibitor resistant advanced breast cancer.

Ruxolitinib and exemestane for estrogen receptor positive, aromatase inhibitor resistant advanced breast cancer.

Journal: NPJ breast cancer
Published: May 04, 2022

Updates on targeting human epidermal growth factor receptor 2-positive breast cancer: what's to know in 2021.

Updates on targeting human epidermal growth factor receptor 2-positive breast cancer: what's to know in 2021.

Journal: Current opinion in obstetrics & gynecology
Published: December 30, 2021
Showing 1-12 of 22

Last Updated: 09/26/2026